Agenda: Ontario Steering Committee for Cancer Drugs (OSCCD)

Date: June 27, 2022 **Time:** 1:00-2:30PM

Microsoft Teams meeting

Time	Topic	Description	Presenter(s)
1:00-1:10	WelcomeAgenda and ObjectivesConflict of Interest (COI) Declarations	Inform members	Interim Chair
1:10-2:10	Cabazitaxel for metastatic castration-resistant prostate cancer – request to modernize eligibility criteria	Submission	Lead/Clinical Presenter Pharmacoeconomics Presenter
2:10-2:25	Trastuzumab in combination with mFOLFOX6 for HER2-positive esophageal, gastroesophageal junction (GEJ), or gastric adenocarcinoma – supplementary information	Request for advice	Presenter
2:25-2:30	 Closing remarks Housekeeping Items 	Inform members	Interim Chair